FEATURED
Cell Surface Targets for Individual Cancer Patients Analyzed with Common Fund Datasets
Given RNA-seq samples from a patient tumor, we screen for targets which are highly expressed in the tumor but lowly expressed across all healthy human tissues in GTEx. Detailed information about the selected target are queried from several DCCs.
FEATURED
Cell Surface Targets for Individual Cancer Patients Analyzed with Common Fund Datasets
Given RNA-seq samples from a patient tumor, we screen for targets which are highly expressed in the tumor but lowly expressed across all healthy human tissues in GTEx. Detailed information about the selected target are queried from several DCCs.
FEATURED
Cell Surface Targets for Individual Cancer Patients Analyzed with Common Fund Datasets
Given RNA-seq samples from a patient tumor, we screen for targets which are highly expressed in the tumor but lowly expressed across all healthy human tissues in GTEx. Detailed information about the selected target are queried from several DCCs.
All Use Cases
Explore different use cases that utilizes data from different CFDE participating programs
Playbook Workflow Builder
Explain MOAs of Side Effects for Approved Drugs
For a side effect and a drug, find differentially expressed genes using the LINCS L1000, literature co-mentions, or GWAS. If overlapping genes are found, compute whether such overlap is statistically significant and visualize the results with a supervenn diagram.
Playbook Workflow Builder
Explain Drug-Drug Interactions
For an adverse event known to be caused by drug-drug interactions, I would like to know if there are overlapping genes between genes that are up or down regulated by the drugs from LINCS and genes associated with the adverse event based on GWAS, literature co-mentions, and genes associated with mouse and human phenotypes.
ProKN
Phosphorylation sites of a perturbagen
Find phosphorylation sites that are likely to be downregulated by a perturbagen
Data Distillery Knowledge Graph
MW2Disease
For a specific disease in Metabolomics Workbench, find all IDG and GTEx assertions that may be related to the disease in a specific tissue type.
Data Distillery Knowledge Graph
Tissue2Drugs
Find all genes that are highly expressed in a GTEx tissue and may be perturbed by a specific compound based on data from the LINCS L1000 dataset, and are known drug targets based on data curated by IDG.
Playbook Workflow Builder
Small Molecules to Induce a Biological Process
We identify genes associated with a biological process from human, mouse phenotypes, KEGG pathways and GO gene set libraries. We then find Consensus LINCS compounds that upregulate these genes for inducing the biological process.
Data Distillery Knowledge Graph
Liquid Biopsy of Dexamethasone Response
Find genes that are up-regulated by dexamethasone, (2) loci expressed in exRNA that overlap RBP binding regions, (3) the RBP that overlaps the locus, and (4) the biofluid(s) where locus was expressed in exRNA.
Playbook Workflow Builder
Compounds to Reverse Disease Signatures
Using differential expression signatures from two independent sources, identify and rank Consensus L1000 Small Molecules capable of reversing the expression signatures. We consider a case study involving Aging signatures between GTEx and GEO, drugs proposed should be considered as potential treatments for aging.
ProKN
Therapeutic pathways in breast cancer
Explore kinase inhibitor drugs and relevant biological pathways that could be targeted in breast cancer patients who didn't respond to the selected treatment therapy.
Data Distillery Knowledge Graph
CES1 Use Case
Display drugs that up or down regulate the gene CES1 from LINCS as well as tissues where it is highly expressed based on assertions from GTEx.
@CFDE Workbench 2026
The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.
The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.
@CFDE Workbench 2026